Peer Review reports
From: Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy
| Original Submission | ||
|---|---|---|
| 14 Jul 2022 | Submitted | Original manuscript |
| 9 Aug 2022 | Author responded | Author comments - Masahiko Ajiro |
| Resubmission - Version 2 | ||
| 9 Aug 2022 | Submitted | Manuscript version 2 |
| 12 Sep 2022 | Reviewed | Reviewer Report |
| 25 Sep 2022 | Reviewed | Reviewer Report |
| 6 Dec 2022 | Author responded | Author comments - Masahiko Ajiro |
| Resubmission - Version 3 | ||
| 6 Dec 2022 | Submitted | Manuscript version 3 |
| 8 Dec 2022 | Author responded | Author comments - Masahiko Ajiro |
| Resubmission - Version 4 | ||
| 8 Dec 2022 | Submitted | Manuscript version 4 |
| 9 Dec 2022 | Author responded | Author comments - Masahiko Ajiro |
| Resubmission - Version 5 | ||
| 9 Dec 2022 | Submitted | Manuscript version 5 |
| 19 Dec 2022 | Author responded | Author comments - Masahiko Ajiro |
| Resubmission - Version 6 | ||
| 19 Dec 2022 | Submitted | Manuscript version 6 |
| 26 Dec 2022 | Reviewed | Reviewer Report |
| 10 Jan 2023 | Reviewed | Reviewer Report |
| Resubmission - Version 7 | ||
| Submitted | Manuscript version 7 | |
| Publishing | ||
| 11 Jan 2023 | Editorially accepted | |
| 20 Jan 2023 | Article published | 10.1186/s12885-023-10540-y |
You can find further information about peer review here.